60 Minutes on Patents, Politics, Policies, and Pricing: Patent Listing Statutes, “Buy America” Policies and Executive Orders, and Recent Hatch-Waxman and BPCIA Amendments Transforming PIV Disputes

April 26, 2022 8:15am

Jay R. Deshmukh
Partner
Kasowitz Benson Torres

Andrei Iancu
Partner
Irell & Manella LLP
(Former Director, U.S. Patent and Trademark Office)

Nicholas Groombridge
Partner
Paul, Weiss, Rifkind, Wharton & Garrison LLP

Joseph Reisman, Ph.D.
Partner
Knobbe Martens

  • Analyzing recent federal and state executive actions and legislation
    • Anticipating the impact on the pharmaceutical industry
      • Patent listing statutes
      • “Buy America” policies and Executive Orders
      • State legislative initiatives
      • Recent Hatch-Waxman and BPCIA amendments
  • Navigating state laws governing transparency in drug pricing
    • Reviewing which states proposed or enacted drug pricing laws
    • Detailing the scope and applicability
  • Appreciating the impact of pharmaceutical patent enforcement trends in the U.S. and around the world
    • Forecasting the impact of the WTO TRIPS waiver for COVID-19 technologies